GlassScriptPhysician profile
Ajay Samir Patel
NPI 1003248907
$10,791.78
in general payments reported to CMS, 2019-2025
29 companies · $5,276 in 2025
The $5,276 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $279 · 2021: $794 · 2022: $649 · 2023: $1,375 · 2024: $1,914 · 2025: $5,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,897 · Travel and Lodging: $1,642 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,896.68 |
| Travel and Lodging | $1,641.89 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,775.27 | 2019-2025 | Clareon, Total30, Clareon Panoptix Pro |
| Biotissue Holdings INC. | $2,491.78 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $829.82 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $602.86 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $602.72 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $405.82 | 2019-2025 | |
| Dompe US, INC. | $204.06 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $189.44 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $184.43 | 2019-2021 | |
| Abbvie INC. | $184.34 | 2022-2024 | |
| Rxsight INC | $178.53 | 2021-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Harrow Eye, LLC | $156.52 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $155.05 | 2020-2023 | |
| Eyevance Pharmaceuticals LLC | $134.97 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $99.70 | 2021-2024 | Tecnis Iol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $97.07 | 2019-2024 | Ce-Marked Kxla System |
| Lkc Technologies, INC. | $88.85 | 2023 | |
| Genzyme Corporation | $71.38 | 2022 | |
| Allergan, INC. | $67.36 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $56.49 | 2023 | Acuvue |
| Avedro INC. | $37.05 | 2019 | |
| Thea Pharma INC. | $36.00 | 2023-2024 | Iyuzeh |
| Sight Sciences, INC. | $29.37 | 2020 | |
| Amgen INC. | $21.22 | 2025 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $20.94 | 2023 | Quatera 700 |
| Ocular Therapeutix, INC. | $20.82 | 2025 | Dextenza |
| Shire North American Group INC | $17.08 | 2019 | |
| Omeros Corporation | $16.82 | 2019 | |
| Alcon Research LLC | $16.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.